EP
EPRX.US Eupraxia Pharmaceuticals Inc. Common Stock
- Market cap
- USD 548M
- P/E
- -
- P/B
- 5.17x
- ROE
- -46.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EPRX.US undervalued?
Graham numberThe Graham number of Eupraxia Pharmaceuticals Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Eupraxia Pharmaceuticals Inc. Common Stock fundamental analysis
No fundamental analysis for Eupraxia Pharmaceuticals Inc. Common Stock yet.
Eupraxia Pharmaceuticals Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophil…
Full company profileEupraxia Pharmaceuticals Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Eupraxia Pharmaceuticals Inc. Common Stock annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -86.6K | -125K | -207K | -117K | -112K | -193K | -210K | -163K | -332K | -535K |
| Operating Income | -4.93M | -12.0M | -6.82M | -2.47M | -18.4M | -17.6M | -21.0M | -27.0M | -38.4M | -66.6M |
| EBITDA | -4.93M | -14.5M | -5.73M | -2.02M | -17.8M | -17.9M | -20.8M | -25.0M | -38.3M | -56.8M |
| Net Income | -4.38M | -13.2M | -7.37M | -4.01M | -24.0M | -18.5M | -21.2M | -25.5M | -38.6M | -56.2M |
| EPS | -0.34 | -1.03 | -0.57 | -0.31 | -1.93 | -0.96 | -0.88 | -0.75 | -0.97 | -0.83 |
| Balance Sheet | ||||||||||
| Total Assets | 5.93M | 2.91M | 3.29M | 1.45M | 31.2M | 25.9M | 15.3M | 34.9M | 86.2M | 134M |
| Total Liabilities | 736K | 14.3M | 21.4M | 23.1M | 12.1M | 16.1M | 14.6M | 3.10M | 5.70M | 13.5M |
| Shareholders' Equity | 5.98M | -11.1M | -17.7M | -21.2M | 20.0M | 10.5M | 1.67M | 33.4M | 82.0M | 121M |
| Cash & Short-term Investments | 4.05M | 823K | 1.16M | 150K | 29.9M | 24.7M | 14.6M | 33.1M | 80.6M | 126M |
| Total Debt | 12.5K | 3.79M | 11.9M | 12.8M | 9.99M | 12.2M | 7.87M | 71.9K | 154K | 3.41M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -5.30M | -8.32M | -5.17M | -404K | -11.6M | -14.4M | -15.6M | -30.0M | -29.0M | -45.2M |
| Capital Expenditure | 315K | 142K | 9.48K | 0.00 | 341K | 236K | 55.2K | 104K | 599K | 833K |
| Free Cash Flow | -5.61M | -8.46M | -5.18M | -404K | -11.9M | -14.6M | -15.7M | -30.1M | -29.6M | -46.0M |
| Ratios | ||||||||||
| ROE | -73.3% | - | - | - | -120.1% | -175.4% | -1,273.4% | -76.3% | -47.0% | -46.5% |
| ROA | -73.9% | -453.4% | -224.4% | -275.6% | -76.7% | -71.4% | -139.3% | -73.0% | -44.8% | -41.9% |
| Debt to Equity | 0.00x | - | - | - | 0.50x | 1.15x | 4.72x | 0.00x | 0.00x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Eupraxia Pharmaceuticals Inc. Common Stock dividends
Eupraxia Pharmaceuticals Inc. Common Stock has not paid dividends in the last 9 fiscal years.
Who owns Eupraxia Pharmaceuticals Inc. Common Stock
- Insiders 11.71%
- Institutions 41.34%
- Public & others 46.95%
- Shares outstanding 67.3M
- Free float 56.8M
Top funds holding EPRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Dynamic Small Business | 2.00M | 3.03% | 0.00% | Jun 2026 |
| Beutel Goodman Small Cap D | 1.69M | 2.55% | -1.31% | Sep 2026 |
| IG Beutel Goodman Canadian Small Cap C | 564K | 0.85% | +0.46% | Jul 2026 |
| Matco Opportunities Series F | 300K | 0.45% | 0.00% | Oct 2026 |
| Biotech Growth Ord | 269K | 0.41% | 0.00% | Jul 2026 |
| SEI Canadian Small Co Equity Cl F | 224K | 0.34% | -2.19% | Sep 2026 |
| PICTON Market Neutral Equity Alt F | 123K | 0.19% | 0.00% | Jun 2026 |
| PICTON Long Short Equity Alternative F | 58.5K | 0.09% | 0.00% | Jun 2026 |
| Dynamic Active U.S. Mid-Cap ETF | 50.4K | 0.08% | 0.00% | Jul 2026 |
| iShares S&P/TSX Small Cap ETF | 46.9K | 0.07% | -1.45% | Oct 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 46.5K | 0.07% | 0.00% | Oct 2026 |
| PICTON Multi-Strategy Alpha Alt F | 32.3K | 0.05% | 0.00% | Jun 2026 |
| PICTON Long Short Eq (130/30) Alt F | 22.1K | 0.03% | 0.00% | Jun 2026 |
| China Universal Gbl YLBJ QDII CNH | 12.5K | 0.02% | 0.00% | Jun 2026 |
| NEI Long Short Equity F | 6.24K | 0.01% | 0.00% | Sep 2026 |
| PICTON Multi-Strategy Alternative F | 463.00 | 0.00% | 0.00% | Jun 2026 |
Top institutions holding EPRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Beutel, Goodman & Company Ltd. | 3.63M | 5.49% | -1.05% | Jun 2026 |
| Affinity Asset Advisors, LLC | 1.65M | 2.50% | +3.84% | Jun 2026 |
| Balyasny Asset Management LLC | 1.35M | 2.04% | +0.00% | Jun 2026 |
| Vivo Capital, LLC | 1.35M | 2.04% | 0.00% | Jun 2026 |
| Scotia Capital Inc | 1.34M | 2.03% | +0.12% | Jun 2026 |
| Partner Fund Management LP | 1.21M | 1.83% | +123.84% | Jun 2026 |
| Great Point Partners LLC | 1.20M | 1.82% | 0.00% | Jun 2026 |
| Jupiter Topco LLC | 1.05M | 1.58% | 0.00% | Jun 2026 |
| Rubric Capital Management LP | 867K | 1.31% | +25.50% | Jun 2026 |
| Ikarian Capital, LLC | 810K | 1.23% | -33.34% | Jun 2026 |
| Woodline Partners LP | 747K | 1.13% | +69.53% | Jun 2026 |
| Point72 Asset Management, L.P. | 730K | 1.11% | -24.52% | Jun 2026 |
| Ameriprise Financial Inc | 711K | 1.08% | +9.54% | Jun 2026 |
| Redmile Group, LLC | 611K | 0.93% | -12.66% | Jun 2026 |
| Seven Fleet Capital Management LP | 611K | 0.92% | +40.89% | Jun 2026 |
| UBS Group AG | 519K | 0.79% | -31.92% | Jun 2026 |
| Citadel Advisors Llc | 502K | 0.76% | +118.10% | Jun 2026 |
| Millennium Management LLC | 442K | 0.67% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 375K | 0.57% | 0.00% | Jun 2026 |
| Picton Mahoney Asset Management | 361K | 0.55% | 0.00% | Jun 2026 |
Eupraxia Pharmaceuticals Inc. Common Stock company profile
- Company name
- Eupraxia Pharmaceuticals Inc. Common Stock
- Ticker
- EPRX.US
- ISIN
- CA29842P1053
- Exchange
- USA Stocks
- Listed since
- Aug 3, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 49
- Fiscal year end
- December
- Address
- 2067 Cadboro Bay Road, Victoria, BC, Canada, V8R 5G4
- Phone
- 250 590 3968
- Website
- eupraxiapharma.com
About Eupraxia Pharmaceuticals Inc. Common Stock
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Eupraxia Pharmaceuticals Inc. Common Stock management
7- Dr. James A. Helliwell FRCPC, M.D.CEO & Director · born 1974
- Mr. Alexander John Rothwell Eng., M.B.A.Chief Financial Officer · born 1969
- Mr. Paul Anthony Brennan B.Sc., M.Sc.Chief Corporate Development Officer
- Ms. Wajida Leclerc B.A., CCP, CHRPExecutive Vice President Corporate Services & People · born 1960
- Mr. Alex TherienExecutive VP of R&D
- Dr. Jeymi Tambiah M.S.Chief Medical Officer
- Dr. Jeffrey Millard Ph.d.Executive Vice President of Technical Operations · born 1976